In Brief This Week: Ariosa Diagnostics; Abbott; Quidel; Precision BioSciences, Cellectis; Vermillion; Rosetta Genomics; BGI; NeoGenomics; Warnex; ClearBridge BioMedics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariosa Diagnostics, formerly known as Aria Diagnostics, said this week that it has completed clinical validation of its Harmony Prenatal Test for non-invasive detection of common fetal trisomies and announced the first medical facility to offer the test. The San Jose, Calif.-based firm said that Atlanta Perinatal Consultants at Northside Hospital in Atlanta is the first to offer the test, which will "become more broadly available in the near future."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.